India needs more investment in healthcare, but it must also ask a harder question: what kind of investment does the sector actually need? A recent report of the Parliamentary Standing Committee on Health and Family Welfare has placed this question at the centre of the policy debate. The Committee has recommended a review and rationalization of Foreign Direct Investment (FDI) rules governing the operation and acquisition of existing private hospitals. It has also warned that aggressive corporatisation and foreign capital could increase healthcare costs. At the same time, it has called for greater foreign investment in medical devices, consumables and specialized medicines, particularly for rare diseases.
This is not an argument against FDI. It is an argument for better-directed FDI. Foreign investment can be highly beneficial to India’s healthcare sector. The country needs capital for modern hospitals, advanced diagnostic equipment, medical technology, pharmaceutical research and specialized treatment. Foreign investors can also bring managerial expertise, technological capabilities and global networks.
The concern arises when FDI is used primarily to acquire existing hospitals rather than create additional healthcare capacity. If a foreign investor acquires a mid-sized hospital that is already serving patients, the transaction may change ownership without adding much productive capacity. If such acquisitions occur repeatedly, they can contribute to consolidation and greater concentration in the hospital market. This raises a legitimate competition-policy question: does foreign capital expand healthcare capacity, or does it increasingly acquire pieces of an existing market? The distinction matters because healthcare is not an ordinary consumer market. Patients often have limited information, cannot easily compare prices and, in emergencies, have little ability to postpone treatment. The bargaining power between providers and patients is therefore inherently unequal.
Foreign ownership, however, is not the problem by itself. Domestic hospital chains can also engage in aggressive pricing or market consolidation. According to the Committee’s report, which cites the 80th round of the National Sample Survey, the average cost of hospitalization was ₹50,508 in private hospitals, compared with ₹6,631 in government hospitals. The average cost in private hospitals was therefore approximately 7.6 times higher than in government hospitals. Although such averages may reflect differences in case mix, treatment intensity and length of stay, the gap nevertheless underscores the scale of India’s healthcare affordability challenge. If private hospitals expand rapidly while public hospitals remain under-resourced, India’s healthcare system could become increasingly divided: high-quality treatment for those who can pay and inadequate access for those who cannot.
This is where the committee’s distinction between different forms of FDI is particularly important. Foreign investment in medical devices, consumables and specialized medicines can generate benefits that extend beyond individual companies. It can create domestic manufacturing capacity, encourage technology transfer, reduce import dependence and strengthen supply chains. India remains heavily dependent on imports for several sophisticated medical technologies. Attracting global companies to manufacture these products domestically could bring capital, technology and skilled employment.
The same logic applies to specialized medicines for rare diseases, where high costs and limited domestic production impose a heavy burden on patients. However, domestic manufacturing alone will not guarantee affordability. Investment in this area should be accompanied by technology transfer, public procurement and negotiated pricing.
India should therefore favour FDI that creates new productive capacity rather than capital that merely changes ownership of existing healthcare assets. Acquisitions should not automatically be treated as unproductive: they can bring new equipment, additional beds and better management. The concern arises when they increase market concentration without expanding effective capacity or improving patient access. The country needs stronger competition policy, transparent pricing, better disclosure of hospital charges and effective regulation of mergers and acquisitions. If a hospital market becomes highly concentrated, regulators should examine whether consolidation is reducing competition.
The most important part of the Committee’s recommendations is its emphasis on strengthening public healthcare. It has proposed autonomous and efficiently managed public multi-speciality hospitals in every revenue division. This could reduce the dependence of patients in smaller towns on metropolitan hospitals for tertiary care. A high-quality public hospital provides patients with an affordable alternative to private care. If government hospitals offer reliable surgery, diagnostics and specialist treatment at substantially lower costs, they can create competitive pressure on private providers.
The Committee has proposed tax incentives, soft loans, subsidized land and concessional electricity to encourage private hospitals in tier-2, tier-3 and rural areas. This is sensible because healthcare infrastructure remains geographically uneven. However, every public incentive should carry a corresponding public obligation. Hospitals that receive subsidized land or concessional financing should provide measurable benefits, such as affordable beds, treatment for economically weaker patients, participation in government insurance programmes and services in underserved areas.
FDI framework
India’s FDI policy for healthcare should become more sector-specific and outcome-oriented. FDI should be encouraged only if; a) it creates new capacity, b) brings technology, c) increases competition and d) improves affordability and access. Foreign investment that primarily produces asset acquisition and market concentration deserves greater scrutiny.
A balanced approach
India cannot build a world-class healthcare system by relying exclusively on either the government or the private sector. The public sector must provide a strong and affordable foundation. The private sector can bring capital, innovation and specialized services. Foreign investors can contribute technology, managerial expertise and global networks.
India should welcome investors who build medical-device factories, develop rare-disease medicines, introduce advanced technologies or establish new hospitals where capacity is scarce. It should be more cautious when investment merely acquires existing hospitals, consolidates the market and strengthens pricing power. The right policy is not less FDI, it is better FDI, with competition, affordability and public value built into the rules.